[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-amd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-amd":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100626242","validation-of-virtual-reality-tests-for-the-assessment-of-patients-with-age-related-macular-degeneration-as-clinical-endpoints-100626242",false,"NCT07433088","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration","VIRETTA","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Sufficient knowledge of the French language\n* Ability to give personal, express, free, and informed consent\n* Ability to comply with the requirements of the protocol\n* Person covered by Social Security\n* Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator\n\nAdditional inclusion criteria for group 1, healthy subjects:\n\n* No detectable visual pathologies\n* Best monocular visual acuity ≥ 8\u002F10\n\nAdditional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy:\n\n* Diagnosis of AMD, early AMD, or intermediate AMD\n* Absence of geographic atrophy\n* Presence of drusen (diameter \\> 63 µm) with or without pigmentary changes\n\nAdditional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal\n* Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nAdditional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Investigator's localization of geographic atrophy: retrofoveal\n* Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nExclusion Criteria:\n\n* Pregnant women, women in labor, or breastfeeding women\n* Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations\n* Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)\n* Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)\n* Known systemic disease that, in the investigator's opinion, would prevent active participation in the study\n* Participation in any other therapeutic study evaluating a drug.\n* Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language.\n* Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).",true,"ALL","50 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease.\n\nVirtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.",[28,29,30],"Dry AMD","Geographic Atrophy","Healhty","NOT_YET_RECRUITING","2026-02-18",{"date":34,"type":35},"2026-02-25","ACTUAL",{"date":37,"type":22},"2026-04",{"date":39,"type":22},"2027-04",{"name":41,"class":42},"Streetlab","INDUSTRY",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100616414","mirabegron-in-patients-with-age-related-macular-degeneration-100616414","NCT07305298","Mirabegron in Patients With Age-Related Macular Degeneration","Mirabegron in Patients With Age-Related Macular Degeneration Treated for Overactive Bladder: A Study Protocol for a Non-Randomized Prospective Controlled Trial","Inclusion Criteria:\n\n* Age subjects 50 and 80 years-old\n* Ability to express informed consent\n* Early or moderate dry AMD according to ARDS classification\n* Overreactive bladder\n* Visual acuity greater than BCVA 65 EDTRS letters.\n\nExclusion Criteria:\n\n* • Any medical condition which contraindicates the use of beta-agonists\n\n  * Uncontrolled hypertension\n  * Tachycardia or atrial fibrillation\n  * Any allergies to the beta-agonists\n  * Renal or hepatic failure\n  * Long QT or concomitant treatment with drugs that cause lengthening of the QT interval\n  * Any sign of ocular inflammation\n  * xudative AMD\n  * Any ongoing medical or surgical treatment for AMD (including intravitreal injections, oral supplementation of lutein, zeaxanthin and or high dietary intake of antioxidants)\n  * Any other ophthalmic diseases such glaucoma, acute or chronic uveitis, advanced cataract, or any opacities of the ocular media that do not permit high-quality imaging examinations.\n  * Pregnancy\n  * Any condition or disease that in the opinion of the investigators may put the subject at significant risk or may interfere significantly with the subject's participation in the study (i. e. malignancy, uncontrolled or cardiovascular diseases)","80 Years",{"count":52,"type":22},312,"OBSERVATIONAL","The goal of this clinical trial is to learn if Mirabegron works to treat dry AMD in patients, aged between 50 and 80 years-old, with early or moderate dry AMD and overactive bladder.\n\nThe main question it aims to answer is:\n\n• Is there any change in outer retina morphology in patients treated?\n\nResearchers will compare the safety and efficacy of mirabegron versus conventional approach (Solifenacin) to treat dry AMD in patients with dry AMD and overactive bladder.\n\nParticipants will:\n\n* Take Mirabegron or Solifenacin every day for 12 months\n* Visit the clinic once every 6 months for checkups and tests",[28,56],"Overactive Bladder","2026-02-04",{"date":59,"type":35},"2026-02-06",{"date":61,"type":22},"2026-04-01",{"date":63,"type":22},"2026-12-01",{"name":65,"class":66},"University of Naples","OTHER",1]